Skip to main content

voretigene neparvovec

Generic: voretigene neparvovec·Brand: Luxturna

voretigene neparvovec: 2 clinical trials tracked.

voretigene neparvovec evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about voretigene neparvovec, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trial Registry Records (2)

An Open-label, Single-arm Study to Provide Efficacy and Safety Data of Voretigene Neparvovec Administered as Subretinal Injection in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

NCT04516369Registry updated 2026-06-04·Phase 3
Completed

Primary endpoint: Change from Baseline in full-field light sensitivity threshold

Interventionalopen4 enrolledStarted 2020-11Completion 2026-051 site · JapanNovartis Pharmaceuticals

A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study

NCT01208389Registry updated 2025-04-29·Phase 1/Phase 2·SPARK

Primary endpoint: Adverse events as a measure of safety and tolerability

Interventionalopen12 targetStarted 2010-11Completion 2027-101 site · United StatesSpark Therapeutics, Inc.